Key Takeaways BSX is set to report Q4 results on Feb. 4, with revenues seen up 15.4% and earnings expected to rise 11.4%. BSX's MedSurg unit is expected to grow 11.4%, led by Endoscopy, Urology gains and Neuromodulation. BSX's Cardiovascular sales are seen up 17.5% on WATCHMAN uptake, FARAPULSE demand and strength. Boston Scientific (BSX) is slated to report fourth-quarter 2025 results on Feb. 4, before market open.The renowned medical device manufacturer posted earnings per share (EPS) of 75 cents in the l ...

Core Insights - Boston Scientific's Endoscopy business is a vital part of its MedSurg segment, focusing on innovative, less invasive technologies for gastrointestinal and pulmonary conditions, with net sales of $2.16 billion in the first nine months of 2025, accounting for 15% of total sales [2][9] - The endoscopy market is valued at $8 billion and is projected to grow at approximately 6% from 2026 to 2028, with Boston Scientific aiming to exceed this growth while improving operating margins [2][9] Business Segments - The Endoscopy portfolio is divided into four key areas, including pancreaticobiliary, which features products like SpyGlass and EXALT D, with plans to launch a capital platform next year to enhance imaging technologies using AI [3] - Endoluminal surgery is another significant area, with innovations such as MANTIS and OverStitch, facilitating the transition from traditional operating rooms to endoscopic therapies through improved tools [4] - The company is also focusing on Endobariatrics, offering minimally invasive weight loss solutions through the Endura Weight Loss Solutions, targeting the obesity market [5] Market Performance - Boston Scientific's shares have increased by 5.5% over the past year, outperforming the industry average increase of 0.1% [8] - The stock is currently trading at a forward five-year Price-to-Earnings (P/E) ratio of 27.90, which is above both its median and the industry average [10] Earnings Estimates - Earnings estimates for Boston Scientific are trending upward, with the current quarter estimate at $0.78 and the next year estimate at $3.45 [11][12]

Core Insights - Boston Scientific (BSX) has a stretched valuation with a Value Score of C, trading at a forward five-year price/earnings (P/E) of 27.77X, which is above its median and the industry average of 20.01X [1] - The company's performance has been mixed over the past year, underperforming key rivals Abbott (ABT) and Medtronic (MDT), but still faring better than the industry and sector [2] Valuation and Market Position - BSX's P/E ratio is higher than the broader Medical sector's P/E of 21.03X, indicating an expensive valuation compared to peers [1] - Key competitors, Abbott and Medtronic, are trading at lower P/E ratios of 22.15X and 20.01X, respectively [1] Business Performance and Growth Drivers - WATCHMAN sales increased by 35% in Q3 2025, supported by growing U.S. concomitant use, while the Electrophysiology (EP) business surged 63% in the same quarter due to FARAPULSE adoption [9][15] - The Urology business is driving strong sales from the global stone management franchise, with expectations of improving growth through 2026 following recent European approvals [10] - Endoscopy is experiencing robust growth in anchor products, and the Intracept procedure for chronic vertebrogenic pain is a significant growth driver in Neuromodulation [11] Strategic Initiatives - Boston Scientific aims to outpace market growth across neuromodulation, urology, and endoscopy, which together serve a global market of $20 billion growing nearly 7% [12] - The planned acquisition of Nalu Medical will expand the portfolio into peripheral nerve pain, presenting additional growth opportunities [12] Future Outlook - Management expects approximately 25% of U.S. WATCHMAN procedures to be performed concomitantly by the end of 2025, with a projected market growth of roughly 20% in the coming years [14] - Analysts remain optimistic about the company's earnings for 2025 and 2026, indicating confidence in its growth trajectory [16] Conclusion - Despite a premium valuation, Boston Scientific's innovative portfolio and strategic execution position it well for long-term growth, particularly through its WATCHMAN and EP products [18]

Core Insights - Boston Scientific (BSX) is set to report its third-quarter 2025 results on October 22, with expectations of strong performance based on previous earnings surpassing estimates [1][8] Group 1: Earnings and Revenue Estimates - The Zacks Consensus Estimate for BSX's Q3 2025 revenues is $4.97 billion, reflecting an 18.1% increase from the same quarter last year [2] - The consensus estimate for earnings per share (EPS) is 71 cents, indicating a 12.7% growth compared to the prior year's quarter [2][3] Group 2: Performance Drivers - The MedSurg division is expected to maintain solid sales momentum, particularly in the Endoscopy business, driven by the Axios platform and technologies like OverStitch and Mantis clip [4] - The Urology business is anticipated to benefit from core franchises and the expanded indication for Rezum, alongside progress from the Axonics acquisition [5] - Neuromodulation growth is likely supported by the Brain and Pain franchises, with positive trends in Deep Brain Stimulation continuing into Q3 [6] - The Cardiovascular segment is projected to perform well, with strong contributions from the Interventional Cardiology Therapies unit and the completion of the SoniVie acquisition [8][9] - The Peripheral Interventions unit is expected to show strong performance, bolstered by recent acquisitions and growth in both arterial and venous product lines [12] Group 3: Market Position and Trends - The MedSurg revenues are estimated at $1.70 billion, suggesting a 15% year-over-year increase [7] - Cardiovascular revenues are expected to improve by 19.6% year over year to $3.27 billion [13] - The company currently holds a Zacks Rank of 2 (Buy), indicating a favorable outlook [15]

Core Insights - Boston Scientific's second-quarter 2025 performance was significantly influenced by its international expansion, particularly in emerging markets, despite facing challenges from currency fluctuations and a tough macroeconomic environment [1][9]. Financial Performance - Year-to-date, Boston Scientific's shares have increased by 18.1%, outperforming the industry and S&P 500, which grew by 7.5% and 8.6% respectively [2]. - The company has a market capitalization of $155.90 billion and has consistently beaten earnings estimates over the past four quarters, with an average surprise of 8.11% [2]. Growth Drivers - The company is focusing on expanding its presence in emerging markets, which showed a robust revenue growth of 12.1% year-over-year in the second quarter of 2025 [3]. - In the EMEA region, sales grew by 1.8% operationally, while the Asia Pacific region saw a significant sales increase of 15.4%, driven by strong performance in China, Japan, Australia, and New Zealand [4]. - The MedSurg segment is a key growth area, with Urology sales increasing by 28% and Endoscopy business growing by 8% globally, supported by strong product performance [5][8]. Challenges - Boston Scientific is exposed to currency fluctuations, with 40% of its sales coming from international markets, leading to a 1.2% revenue headwind in Q2 2025 due to unfavorable foreign exchange rates [7][8]. - The company is also facing macroeconomic challenges, including geopolitical tensions and supply chain disruptions, which are expected to impact profitability and result in a tariff cost of approximately $100 million for the full year 2025 [9]. Future Outlook - The Zacks Consensus Estimate for 2025 earnings per share has increased by 2.1% to $2.91, with revenue estimates set at $19.49 billion, reflecting a 16.4% increase from the previous year [10].

Core Insights - Boston Scientific (BSX) is expected to report its second-quarter 2025 results on July 23, with prior EPS of 75 cents exceeding estimates by 11.94% [1] - The company has consistently surpassed earnings estimates over the last four quarters, with an average surprise of 8.79% [1] Revenue and EPS Estimates - The Zacks Consensus Estimate for BSX's Q2 2025 revenues is $4.89 billion, reflecting an 18.7% increase year-over-year [2] - The EPS estimate for Q2 2025 is projected at 72 cents, indicating a 16.1% rise compared to the previous year [2] Performance Influencers - The MedSurg division is anticipated to maintain strong sales momentum, particularly in the Endoscopy business, driven by the Axios platform and technologies like OverStitch and Mantis clip [4] - The Urology business is expected to benefit from its core stone management franchise and the integration of the Axonics acquisition [5] - Neuromodulation growth is likely supported by the Brain and Pain franchises, with positive trends from Deep Brain Stimulation and the Intercept product [6] Segment Performance - MedSurg revenues are estimated at $1.68 billion, a 13.1% year-over-year increase [7] - The Cardiovascular unit is projected to perform well, with revenues expected to rise 8.3% year-over-year to $719.95 million [14] - Key contributors to Cardiovascular growth include the AGENT Drug-Coated Balloon and the completion of the SoniVie acquisition [10][11] Earnings Expectations - Boston Scientific has an Earnings ESP of +0.88%, indicating a higher likelihood of beating estimates [15] - The company holds a Zacks Rank of 2 (Buy), suggesting favorable conditions for earnings performance [16]

Core Insights - Boston Scientific's Endoscopy business is strategically positioned to benefit from the expanding global endoscopy devices market, which is projected to grow from $28.1 billion in 2022 to $44.1 billion by 2032 at a CAGR of 4.6% from 2023 to 2032 [1] Company Performance - Sales of Endoscopy products reached $673 million in Q1 2025, reflecting a 6% increase both operationally and organically, accounting for 14% of the company's overall revenues [2][8] - The growth in sales is attributed to steady performance across geographies and a diverse product suite, with notable double-digit growth in the AXIOS Stent and Electrocautery Enhanced Delivery System [3][8] - The Endoluminal Surgery franchise also experienced double-digit growth driven by innovative technologies such as OverStitch and MANTIS Clip, indicating strong adoption of advanced endoscopic tools [4] Competitive Landscape - Stryker's Endoscopy segment reported a strong 11.1% increase in U.S. organic sales, driven by double-digit gains in core endoscopy and sports medicine portfolios [5] - Johnson & Johnson, through its subsidiary Ethicon, is a key competitor, focusing on advanced energy-based endoscopic surgery platforms and digital surgery initiatives [6] Stock Performance - Boston Scientific's shares have increased by 27.3% over the past year, outperforming the industry growth of 9.7% and the S&P 500's growth of 11% during the same period [7] Valuation Metrics - The company trades at a forward 12-month price-to-earnings ratio (P/E) of 32.13X, which is above the industry average of 21.33X [9] Earnings Estimates - The Zacks Consensus Estimate for Boston Scientific's earnings has been on the rise over the past 60 days, indicating positive sentiment regarding future performance [11]